Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial.
Wilkinson TMA, Schembri S, Brightling C, Bakerly ND, Lewis K, MacNee W, Rombo L, Hedner J, Allen M, Walker PP, De Ryck I, Tasciotti A, Casula D, Moris P, Testa M, Arora AK. Wilkinson TMA, et al. Among authors: casula d. Vaccine. 2019 Sep 24;37(41):6102-6111. doi: 10.1016/j.vaccine.2019.07.100. Epub 2019 Aug 22. Vaccine. 2019. PMID: 31447126 Free article. Clinical Trial.
Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.
Andreas S, Testa M, Boyer L, Brusselle G, Janssens W, Kerwin E, Papi A, Pek B, Puente-Maestu L, Saralaya D, Watz H, Wilkinson TMA, Casula D, Di Maro G, Lattanzi M, Moraschini L, Schoonbroodt S, Tasciotti A, Arora AK, Maltais F; NTHi-Mcat-002 study group. Andreas S, et al. Among authors: casula d. Lancet Respir Med. 2022 May;10(5):435-446. doi: 10.1016/S2213-2600(21)00502-6. Epub 2022 Jan 10. Lancet Respir Med. 2022. PMID: 35026180 Clinical Trial.
Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial.
De Smedt P, Leroux-Roels G, Vandermeulen C, Tasciotti A, Di Maro G, Dozot M, Casula D, Annaratone M, Riccucci D, Arora AK. De Smedt P, et al. Among authors: casula d. Vaccine X. 2021 Nov 3;9:100124. doi: 10.1016/j.jvacx.2021.100124. eCollection 2021 Dec. Vaccine X. 2021. PMID: 34820619 Free PMC article.
Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study.
Galgani I, Annaratone M, Casula D, Di Maro G, Janssens M, Tasciotti A, Schwarz T, Ferguson M, Arora AK. Galgani I, et al. Among authors: casula d. Respir Res. 2022 May 4;23(1):114. doi: 10.1186/s12931-022-02019-4. Respir Res. 2022. PMID: 35509077 Free PMC article. Clinical Trial.
A detailed analysis of possible efficacy signals of NTHi-Mcat vaccine against severe COPD exacerbations in a previously reported randomised phase 2b trial.
Arora AK, Chinsky K, Keller C, Mayers I, Pascual-Guardia S, Vera MP, Lambert C, Lombardi S, Rondini S, Tian S, Ulloa-Montoya F, Moraschini L, Casula D; NTHi-Mcat-002 study group. Arora AK, et al. Among authors: casula d. Vaccine. 2022 Sep 29;40(41):5924-5932. doi: 10.1016/j.vaccine.2022.08.053. Epub 2022 Sep 6. Vaccine. 2022. PMID: 36068109 Free article. Clinical Trial.
Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.
Kerdpanich P, Chanthavanich P, De Los Reyes MR, Lim J, Yu D, Ama MC, Mojares Z, Casula D, Arora AK, Pellegrini M. Kerdpanich P, et al. Among authors: casula d. PLoS Negl Trop Dis. 2018 Jun 6;12(6):e0006340. doi: 10.1371/journal.pntd.0006340. eCollection 2018 Jun. PLoS Negl Trop Dis. 2018. PMID: 29874228 Free PMC article. Clinical Trial.
125 results